According to Collegium Pharmaceutical
's latest financial reports the company has $0.31 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $0.31 B | 78.8% |
2022-12-31 | $0.17 B | -6.83% |
2021-12-31 | $0.18 B | 7.07% |
2020-12-31 | $0.17 B | 2.41% |
2019-12-31 | $0.17 B | 15.95% |
2018-12-31 | $0.14 B | 23.54% |
2017-12-31 | $0.11 B | -22.53% |
2016-12-31 | $0.15 B | 60.11% |
2015-12-31 | $95.69 M | 5756.61% |
2014-12-31 | $1.63 M | -78.36% |
2013-12-31 | $7.55 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
![]() United Therapeutics UTHR | $2.99 B | 864.13% | ๐บ๐ธ USA |
![]() Agile Therapeutics
AGRX | $2.87 M | -99.07% | ๐บ๐ธ USA |
![]() Horizon Therapeutics
HZNP | $2.46 B | 693.64% | ๐ฎ๐ช Ireland |
![]() KemPharm KMPH | $82.84 M | -73.32% | ๐บ๐ธ USA |